Mankind Pharma on Monday announced its financial results for the third quarter and nine months ended 31st December 2025 with an 11.5 percent year-on-year increase in consolidated revenue from operations to ₹3,567 crore.
Domestic revenue rose 11.1 percent year-on-year to ₹3,046 crore, while export revenue increased 14.1 percent to ₹521 crore. The company posted an adjusted EBITDA of ₹923 crore, with an adjusted EBITDA margin of 25.9 percent. Profit after tax for the quarter stood at ₹414 crore, up 9.5 percent year-on-year, with a PAT margin of 11.6 percent. Diluted earnings per share for Q3FY26 came in at ₹9.9, reflecting a 6.7 percent year-on-year growth.
For the nine months ended December 31, 2025, Mankind Pharma’s revenue from operations increased 18.7 percent year-on-year to ₹10,835 crore. Domestic revenue during the period grew 14.8 percent to ₹9,331 crore, while exports surged 50.8 percent to ₹1,504 crore. Adjusted EBITDA for the nine-month period stood at ₹2,696 crore, translating into a margin of 24.9 percent. Profit after tax declined 12.6 percent year-on-year to ₹1,379 crore, and diluted EPS stood at ₹32.9.
Rajeev Juneja – Vice Chairman & Managing Director said, “Mankind’s revenue increased 11.5% YoY, with adj. EBITDA margins1 of 25.9%, primarily due to improvement in domestic pharma and BSV consolidation. Mankind’s chronic share increased by 200bps YoY to 39.3% driven by strong growth of 16.7% in cardiac and 14.4% in anti-diabetes. Revenue from OTC grew by 5.2% in Q3FY26 vs -2.6% in Q2FY26. We expect growth to improve further. BSV growth initiatives progressing well; Strong double-digit growth in Q3. We remain confident of delivering long term sustainable growth anchored by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and super specialty BSV portfolio.”
In the consumer healthcare segment, revenue grew 5.2 percent year-on-year during the quarter, reversing a decline of 2.6 percent in the previous quarter. Modern trade and e-commerce contribution increased to 13.1 percent in Q3FY26 compared to 9.8 percent in the year-ago period.
Export growth was primarily driven by the BSV international business. Excluding BSV, the company launched four new products during the first nine months of FY26, taking the total number of products launched in the US to 48.
Also Read